The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1307
March 9, 2009
View Complete Issue         Table of Contents 2019 
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
March 9, 2009 (Issue: 1307)
Alemtuzumab (Campath), a genetically engineered, humanized monoclonal antibody currently approved to treat B-cell chronic lymphocytic leukemia (BCLL) and used off-label for induction therapy in solid organ transplants, is now also being tried...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Alemtuzumab (Campath) Off-Label for Relapsing Multiple Sclerosis
Article code: 1307a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.